# Parand Darou Co.

## Health Beyond Boundaries

# Products Overview

# API

| Product | Standard | CAS. No |
|---|---|---|
| Buprenorphine HCl | USP , BP | 53152-21-9 |
| Naltrexone Hydrochloride | USP, BP | 850808-02-5 |
| Oxycodone Hydrochloride | USP, BP | 124-90-3 |
| Methadone Hydrochloride | USP, BP | 1095-90-5 |
| Noscapine | USP, BP, JP | 128-62-1 |
| Noscapine Hydrochloride | EP,BP, JP | 912-60-7 |
| Codeine phosphate hemihydrate | USP, BP | 41444-62-6 |
| Codeine | USP | 76-57-3 |
| Morphine Sulfate | USP, BP, IP | 6211-15-0 |
| Morphine Hydrochloride | EP, BP | 6055-06-7 |
| Papaverine Hydrochloride | USP, BP | 61-25-6 |
| Empagliflozin | In House | 864070-44-0 |
| Sitagliptin Phosphate | USP, BP | 654671-77-9 |
| Dapagliflozin Propanediol | USP | 960404-48-2 |
| Opium Tincture 1% Bulk | USP | 8029-99-0 |



# API

## Under Development Products

( Coming soon )

| Product | Standard | CAS. No |
|---|---|---|
| Naloxone Hydrochloride | USP, BP | 51481-60-8 |
| Tramadol Hydrochloride | USP, BP | 36282-47-0 |
| Oxymorphone Hydrochloride | USP | 357-07-3 |
| Hydrocodone Bitartrate | USP, BP | 34195-34-1 |
| Dihydrocodeine Phosphate | JP | 24204-13-5 |
| Dihydrocodeine Tartrate | USP, BP | 5965-13-9 |
| Rivaroxaban | BP | 366789-02-8 |



# Intermediate Products Overview

| Product | Standard | CAS. No |
|---|---|---|
| Buprenorphine | In house | 52485-79-7 |
| Norbuprenorphine | In house | 78715-23-8 |
| 3-O-Methyl Norbuprenorphine | In house | 16614-59-8 |
| Buprenorphine 3-O-Methyl Ether | In house | 16524-65-5 |
| Naltrexone | In house | 16590-41-3 |
| Naloxone | In house | 465-65-6 |
| Noroxymorphone Hydrochloride | In house | 33522-95-1 |
| Dihydrocodeine | In house | 125-28-0 |
| Oxymorphone | In house | 76-41-5 |
| Hydrocodone | In house | 125-29-1 |
| Papaverine Technical Grade | In house | 58-74-2 |
| Noscapine Technical Grade | In house | 128-62-1 |
| Morphine Technical Grade | In house | 57-27-2 |
| Codeine Technical Grade | In house | 76-57-3 |

# Products Overview

| Product Name | Generic |
|---|---|
| PD Nosca (Syrup) | Noscapin |
| Paxadone 325/5 (Tab) | Acetaminophen/Oxycodone 325/5 |
| Paxadone 325/10 (Tab) | Acetaminophen/Oxycodone 325/10 |
| Brudon 400/5 (Tab) | Ibuprofen/Oxycodone 400/5 |
| Oxycodone 5 (Tab) | |
| Oxycodone 15 (Tab) | |
| Oxycodone 30 (Tab) | |
| Opium Tincture 1% (Syrup) | |

## Finished Product

## (Coming soon)

**Under Development Products – Pharmaceutical Materials**

Parand Darou Pharmaceutical Company, with its expertise and experience in producing high-quality Pharmaceutical Materials, is constantly developing and researching to offer new and more effective products. Currently, a range of important Pharmaceutical Materials are in the final stages of development and will soon be introduced to the market. These Pharmaceutical Materials belong to various therapeutic categories and are designed to enhance the quality of life for patients. These products are undergoing various research and laboratory phases, and once approved, they will be launched into the market. Parand Darou is committed to offering innovative and efficient medicines in the pharmaceutical industry, always striving to meet the therapeutic needs of society.

| Coming soon | Standard | CAS. No |
|---|---|---|
| Metocarbamol/ Ibuprofen (Tab) | USP | CAS [532-03-6] |
| Tramadol 200 Sustained-Release (SR) | USP | CAS [532-03-6] |
| Buprenorphine 8/2/0.4 (Tab) | | |
| Methadone 40/20 (Tab) | | |

## Parand DarouPharmaceutical Co.

Parand Darou Pharmaceutical Company, as one of the leading knowledge-based companies in Iran pharmaceutical industry, has taken significant steps over the past three years toward sustainable development, technological innovation and an active presence in international markets. Established in 2006 with a specialized focus on the production of narcotic medicines. Parand Darou is now recognized as the second private company officially licensed by the Iran Food and Drug Administration to manufacture these products and now playing a vital role in advancing the country's pharmaceutical sector.

During the past three years, the company has achieved exports exceeding five million USD, successfully entering markets such as China, Russia, Chile, Kenya, India, El Salvador, Iraq and Nigeria. while also obtaining GMP certification for its knowledge-based production lines. These milestones have established Parand Darou as a prominent producer and exporter of narcotic pharmaceuticals. In line with its forward-looking vision, Parand Darou is continuing to expand active pharmaceutical ingredient (API) production lines, diversify its product portfolio and execute precise planning for the launch of 27 new formulations. While is Committed to professional ethics, innovation, integrity and social responsibility, dedicated to safeguarding public health, improving quality of life, and protecting the environment. With the acquisition of Parand Darou's managerial shares by Kimyagaran Emrooz Chemical Industries, a knowledge-based enterprise, the company has placed synergy of knowledge and expertise at the core of its progressive journey.

**Address**: Parand Darou Co., 2nd Karegar St., Karegar Blvd., Azadegan St., Imam Khomeini Blvd., Kaveh Industrial City, Saveh-Iran, Postal Code:3914319783
**Phone:** +98-21-92001602 - +98-21-92001601
**Website:** www.Paranddarou.co
**Email:** info@Paranddarou.co
Marketing@paranddarou.co